Search results
Results from the WOW.Com Content Network
Treatment guidance for health workers can be found in the WHO publication Treatment of mycobacterium ulcerans disease (Buruli ulcer). A recent study suggests the combination of rifampicin (10 mg/kg once daily) and clarithromycin (7.5 mg/kg twice daily) is now the recommended treatment.
Early detection and antibiotics are crucial for treating Buruli ulcers. When you become infected by the bacteria, your skin gets destroyed by a toxin called mycolactone. What starts as a small...
Early diagnosis and treatment are crucial to minimizing morbidity, costs and prevent long-term disability. Symptoms of Buruli ulcer begin with painless nodules and swelling, usually on the arms and legs and sometimes on other parts of the body.
The most commonly used antibiotics for treating BU are rifampicin, streptomycin, and clarithromycin; efforts have recently been made to introduce new treatments that increase the effectiveness and adherence to therapy.
What is the treatment of Buruli ulcer? Current WHO recommendations for treatment are as follows: A combination of rifampicin and either streptomycin, amikacin, clarithromycin, moxifloxacin or ciprofloxacin for eight weeks as a first-line treatment for all forms of the active disease.
Treatment of Buruli ulcers relies on timely and accurate diagnoses. When treated early, antibiotics alone are adequate. If treatment is delayed, surgical debridement, skin grafts,...
Since the first description of the disease in 1948, the standard treatment for Buruli ulcers was extensive surgical debridement of affected skin and surrounding tissue, with or without subsequent skin grafting (Darie 1994; van der Werf 2003).